Equibles does not estimate personal net worth.
Get an email with a short summary when Palvella Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get PVLA alertsJeffrey Martini is recorded as CTO at Palvella Therapeutics, Inc. (PVLA) since December 13, 2024. Palvella Therapeutics, Inc. reported in an 8-K filed December 16, 2024 that Jeffrey Martini was appointed Chief Scientific Officer, effective December 13, 2024. Jeffrey Martini has spoken on 2 earnings calls across 1 company, most recently for Palvella Therapeutics, Inc. on August 4, 2026. Palvella Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Palvella Therapeutics, Inc. includes Wesley H. Kaupinen (CEO and Board Member), George M. Jenkins (Chairman and Board Member), James Geraghty (Chairman) and 7 others.
“In connection with the Merger and pursuant to the Merger Agreement, at the Effective Time, the following individuals were appointed to serve as executive officers and directors of the Company: Jeffrey Martini, Ph.D. | 47 | Chief Scientific Officer”
“As you've heard this morning, Pavela has built tremendous momentum across the business.”
“I want to spend a minute on the qualitative data generated from our patient interviews in Selva because this is something that's really important to Palvella and to regulators, particularly in rare diseases where there are no approved therapies and no regulatory precedent.”
2024-12-13–present
Proxy statement
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
CTO
2024-12-13–present
